Oxcarbazepine

Introduction Overview

Generic Name

oxcarbazepine

Brand Name

Oxtellar XR, Trileptal

Dosage Form

oral suspension (300 mg/5 mL), oral tablet (150 mg, 300 mg, 600 mg), oral tablet extended release (150 mg, 300 mg, 600 mg)

Drug Class

Dibenzazepine anticonvulsants

Pharmacokinetics

Absorption:
Oxcarbazepine is rapidly and well absorbed from the gastrointestinal tract following oral administration. The extended-release formulations are designed to delay the absorption, resulting in a smoother plasma concentration-time profile. Peak plasma concentrations of the active metabolite, 10-monohydroxy derivative (MHD), are typically reached approximately 4.5 to 6 hours after administration of the standard oxcarbazepine formulation and around 7 to 9 hours post-dose for extended-release tablets. Food has minimal effect on the extent of absorption but may slightly delay the time to peak concentration, particularly with extended-release formulations. The bioavailability of oxcarbazepine is approximately 60-80%, considering that active drug distribution is mainly via its metabolite MHD.

Distribution:
Oxcarbazepine itself demonstrates moderate plasma protein binding (approximately 40%), while its active metabolite, MHD, shows low plasma protein binding of around 40%. The volume of distribution (Vd) of MHD is approximately 0.8 ± 0.2 L/kg, indicating moderate distribution into bodily tissues. The drug and its active metabolite can cross the blood–brain barrier efficiently, reaching adequate concentrations in the central nervous system, which is crucial for its antiepileptic activity. Oxcarbazepine and MHD are also detected in cerebrospinal fluid at levels correlating with plasma concentrations, contributing to therapeutic effects.

Metabolism:
Oxcarbazepine is extensively metabolized in the liver by cytosolic enzymes, predominantly via reduction to its pharmacologically active metabolite, the 10-monohydroxy derivative (MHD). Unlike carbamazepine, oxcarbazepine does not undergo extensive cytochrome P450-mediated metabolism, leading to fewer interactions and a lower potential for significant hepatic enzyme induction. The metabolism circumvents the epoxide intermediate responsible for some toxic effects in related agents. MHD is subsequently conjugated via glucuronidation to inactive metabolites, which are then eliminated primarily by renal excretion. Metabolic clearance is efficient, and the process is not significantly affected by hepatic impairment, although caution is advised.

Elimination:
The primary route of elimination of oxcarbazepine metabolites is renal excretion. Approximately 95% of the drug and its metabolites are excreted via the kidneys, mostly as glucuronide conjugates of MHD. The elimination half-life of MHD ranges between 8 to 10 hours in healthy adults, supporting twice-daily dosing in clinical use. Factors such as age, renal function, and concomitant medications can affect the elimination rate. In patients with renal impairment, clearance is reduced, requiring dose adjustments. Oxcarbazepine itself has negligible renal excretion, and unchanged drug is rarely detected in urine. The metabolite MHD clearance may be slightly increased by enzyme-inducing antiepileptic drugs, necessitating clinical monitoring.

Dosage Forms

Available Dosage Forms:
Oxcarbazepine is available in multiple oral formulations to accommodate various patient needs and age groups. These formulations include:
- Oral suspension: 300 mg per 5 mL, designed for pediatric use or patients unable to swallow tablets.
- Oral tablets (immediate release): 150 mg, 300 mg, and 600 mg strengths allow flexible dose titration.
- Oral extended-release tablets: 150 mg, 300 mg, and 600 mg, facilitating once or twice-daily dosing with sustained drug exposure.

Dosages for Adults and Adolescents:
For monotherapy or adjunctive therapy in partial seizures, the initial dose generally starts at 300 mg twice daily, with gradual titration upward based on therapeutic response and tolerability. Maintenance doses commonly range from 600 mg to 2400 mg per day, divided into one or two doses depending on the formulation used. Extended-release tablets allow for once-daily dosing in some cases, enhancing compliance. Pediatric dosing varies by age and weight, with adjustments made accordingly. Clinical guidelines emphasize gradual dose escalation to reduce adverse effects.

Specific Patient Populations:
In pediatric patients, oxcarbazepine oral suspension and tablets are approved for varying minimum ages depending on indication and use as monotherapy or adjunctive therapy. The suspension is especially useful in children as young as 2 years when used adjunctively, whereas extended-release tablets are reserved for children above 6 years old. Renal impairment necessitates dose reductions due to decreased clearance of active metabolites. In elderly patients, lower starting doses and careful titration are advised to minimize side effects. Pregnant women require careful risk-benefit assessment given potential teratogenic risks and seizure control needs. Breastfeeding is not recommended during oxcarbazepine therapy due to potential drug transmission through breast milk.

Mechanism Of Action

Oxcarbazepine exerts its antiepileptic activity primarily through modulation of voltage-gated sodium channels in neuronal membranes. By stabilizing the inactive state of these sodium channels, it reduces sustained repetitive neuronal firing and inhibits the propagation of seizure activity. This sodium channel blockade decreases the excessive neuronal excitability that underlies epileptic discharges. Unlike carbamazepine, oxcarbazepine does not form harmful epoxide metabolites, contributing to a more favorable safety profile.

Upon oral administration, oxcarbazepine is rapidly metabolized in the liver to its active metabolite, the 10-monohydroxy derivative (MHD), which is responsible for the majority of its pharmacological effects. MHD's action on sodium channels leads to dampening of high-frequency neuronal firing without significantly impairing normal neuronal function, thus maintaining normal CNS activity while preventing seizures.

Additionally, oxcarbazepine and MHD may modulate hyperexcitable neurons indirectly by affecting potassium channels and calcium channels, although these effects are less well characterized. These multiple ion channel interactions contribute to overall neuronal stabilization. Furthermore, oxcarbazepine's minimal influence on cytochrome P450 enzymes reduces its potential for drug-drug interactions compared to related antiepileptics.

Clinically, oxcarbazepine’s mechanism leads to effective control of partial seizures, both as monotherapy and adjunctive therapy, with fewer neurotoxic side effects than carbamazepine. Comparative studies demonstrate similar efficacy but improved tolerability, making it a preferred option in patients who cannot tolerate carbamazepine. Ongoing research investigates oxcarbazepine’s off-label use in mood disorders and neuropathic pain, reflecting its modulatory effects on neuronal excitability.

Pharmacological Actions

Voltage-gated sodium channel blockade leading to decreased neuronal excitability.
Stabilization of inactive state of neuronal sodium channels preventing seizure propagation.
Active metabolite (MHD) mediates primary anticonvulsant effect.
Modulation of potassium and calcium ion channels contributing to neuronal stabilization.
Reduction in excessive repetitive firing of action potentials in hyperexcitable neurons.
Minimal induction of hepatic enzymes, reducing drug-drug interaction potential.
Regulation of neurotransmitter release secondary to ion channel modulation.
Control of partial seizures as both monotherapy and adjunctive therapy.
Possible modulation of glutamatergic and GABAergic neurotransmission indirectly.
Antiepileptic effect without formation of toxic epoxide metabolites compared to carbamazepine.
Potential mood-stabilizing properties observed in some clinical studies.
Decrease in nerve impulse transmission associated with neuropathic pain.
Extended-release formulation allows sustained pharmacological action over 24 hours.
Neuroprotective effects suggested by reduction in seizure-related neuronal damage.

Therapeutic Or Clinical Uses

Treatment of partial seizures with or without secondary generalization in adults and pediatric patients.
Monotherapy for partial seizures in adults and children aged 4 years and older (Trileptal).
Adjunctive therapy for partial seizures in children aged 2 years and older and adults.
Treatment of epilepsy where sodium channel blockade is indicated.
Off-label use in treatment of neuropathic pain disorders due to neuronal excitability modulation.
Potential use as mood stabilizer in bipolar disorder under investigation.
Management of seizure control in patients intolerant to carbamazepine therapy.
Adjunctive therapy in refractory focal epilepsy cases.
Used in combination with other antiepileptic drugs to enhance seizure control in resistant epilepsy.
Treatment of seizures during pregnancy under careful medical supervision.
Reduction of seizure frequency and severity improving quality of life in epileptic patients.
Use in pediatric epilepsy to control partial seizures with a liquid formulation option.
Treatment option for patients requiring fewer drug interactions and improved tolerability.
Alternative therapy in patients with contraindications to older anticonvulsants.
Supportive therapy to prevent seizure recurrence following brain injury or surgery.

Side Or Adverse Effects

Dizziness commonly reported, especially during initiation and dose escalation.
Somnolence and drowsiness affecting cognitive and motor functions.
Tiredness and fatigue impacting daily activities.
Impaired balance, coordination difficulties (ataxia), especially in higher doses.
Nausea and vomiting occasionally occurring during therapy.
Tremors or involuntary shaking observed in some patients.
Visual disturbances, including blurred or double vision (diplopia).
Skin rash ranging from mild to severe hypersensitivity reactions (including Stevens-Johnson Syndrome).
Hyponatremia (low sodium levels) leading to confusion, weakness, and seizures; can be life-threatening.
Serious drug reactions such as hypersensitivity syndrome with fever, swollen glands, and flu-like symptoms.
Mood changes including depression, anxiety, irritability, and rare suicidal ideation.
Allergic reactions presenting with hives, swelling of face, lips, or throat requiring emergency care.
Increased seizure frequency if drug is abruptly discontinued.
Potential for increased liver enzymes or hepatic effects in rare cases.
Cognitive impairment or memory difficulties in some patients during dose adjustment.

Precautions

Avoid sudden discontinuation to prevent rebound seizures or status epilepticus.
Monitor serum sodium levels periodically due to risk of hyponatremia, especially in elderly and patients on diuretics.
Use cautiously in patients with pre-existing liver or kidney disease; adjust doses accordingly.
Assess psychiatric history due to risk of mood alterations and suicidal thoughts.
Inform patients about the possibility of dizziness and sedation; caution when driving or using machinery.
Avoid alcohol consumption as it may increase CNS depressive effects and seizure risk.
Be vigilant for signs of serious skin reactions; discontinue drug immediately if rash or systemic symptoms occur.
Use pregnancy registry data and closely monitor pregnant patients due to potential teratogenic risks.
Advise female patients on effective contraception as oxcarbazepine may reduce hormonal contraceptive efficacy.
Do not breastfeed while on therapy due to potential drug transmission and adverse effects in infants.
Adjust dosing and monitor therapeutic response in pediatric and elderly populations carefully.
Consider drug interaction potential with other CNS depressants and enzyme-inducing agents.
Educate patients to report any new or worsening psychiatric or allergic symptoms immediately.
Store oral suspension properly and discard after recommended period to maintain drug stability.

Warnings

Serious hypersensitivity reactions including rash, fever, swollen glands, and systemic manifestations require immediate medical attention.
Hyponatremia with severe symptoms such as confusion, weakness, muscle pain, and increased seizures can be life-threatening.
Potential suicidal ideation and behavior reported in patients taking seizure medications; monitor all patients closely.
Abrupt withdrawal can precipitate status epilepticus; taper dosing gradually under medical supervision.
Not safe to use concurrently with certain medications that may alter oxcarbazepine levels or increase side effects without dose adjustment.
Use during pregnancy only when benefits outweigh risks; seizures themselves pose significant risk to mother and fetus.
Oxcarbazepine may reduce effectiveness of hormonal contraceptives leading to unplanned pregnancy.
Do not exceed prescribed dosage; overdose can lead to severe neurological impairment requiring emergency treatment.
Patients should avoid alcohol and other CNS depressants to prevent additive sedation and impaired cognition.
Close monitoring is essential in patients with renal impairment due to altered drug clearance.
Discontinue if severe rash or symptoms consistent with Stevens-Johnson Syndrome or toxic epidermal necrolysis occur.
Use caution in patients with a history of hypersensitivity to carbamazepine or eslicarbazepine due to cross-reactivity.
Monitor electrolytes and neurologic status regularly to detect early signs of adverse reactions.
Warn patients and caregivers to recognize behavioral changes signaling emerging psychiatric adverse events.

Contraindication

Known hypersensitivity to oxcarbazepine or its active metabolite MHD.
History of hypersensitivity or allergic reactions to carbamazepine due to potential cross-reactivity.
Patients with a history of serious skin reactions such as Stevens-Johnson Syndrome associated with oxcarbazepine or related compounds.
Hypersensitivity to eslicarbazepine acetate or chemically related dibenzazepine derivatives.
Use in patients with severe hepatic impairment without careful consideration and monitoring.
Not recommended for use in patients with documented hyponatremia unless benefits outweigh risks.
Children below approved age limits for specific formulations and indications (e.g., extended-release tablet not approved under age 6).
Patients with severe renal impairment without dose adjustment and frequent monitoring.
Concomitant use with certain drugs contraindicated due to severe interaction potential (e.g., some CYP inhibitors).
Use is contraindicated in patients with untreated narrow-angle glaucoma due to mydriatic effects reported with similar compounds.
Avoid use in patients with known hypersensitivity to any excipients in the formulation.
Use caution and thorough evaluation before initiation in patients with unstable mood disorders.
Pregnancy category considerations limit use where safer alternatives are available unless seizure control is imperative.
Not for intravenous administration or use outside approved oral formulations.

Drug Interactions

Oxcarbazepine induces hepatic cytochrome P450 enzymes (notably CYP3A4), decreasing plasma concentrations of concomitant drugs such as oral contraceptives, reducing their effectiveness.
Concomitant use with other antiepileptic drugs (e.g., phenytoin, carbamazepine, phenobarbital) may alter oxcarbazepine metabolism or increase toxicity risk.
Enzyme inducers can increase clearance of oxcarbazepine's active metabolite MHD, necessitating dose adjustments.
CNS depressant drugs including benzodiazepines, opioids, muscle relaxants, and alcohol may potentiate sedation and impair motor skills.
Drugs that alter sodium levels (e.g., diuretics) may increase risk or severity of oxcarbazepine-induced hyponatremia.
Interactions with certain psychotropic medications may exacerbate CNS side effects or alter plasma levels.
Combination with lithium requires monitoring due to altered renal clearance and risk of neurotoxicity.
Oxcarbazepine does not significantly affect cytochrome P450 2C9 or 2C19 but care is advised with drugs metabolized by these enzymes.
Coadministration with valproic acid may lead to pharmacodynamic interactions affecting seizure control.
Oral contraceptive efficacy is reduced; additional non-hormonal contraception recommended during treatment and for one month after discontinuation.
Interactions with warfarin and other anticoagulants may occur, requiring monitoring of coagulation parameters.
Herbal supplements such as St John’s Wort may reduce oxcarbazepine plasma concentrations.
Contraindicated or requiring caution with drugs that significantly alter electrolyte balance.
Concurrent use of other medications that cause QT prolongation requires careful monitoring.
Interaction profiles necessitate adjustment and close clinical monitoring during polypharmacy.

Preparations Of The Drug

Oral suspension: 300 mg/5 mL - indicated for pediatric patients and those who cannot swallow tablets, requires shaking before dosing and shelf life of 7 weeks after opening.
Immediate release oral tablets available in 150 mg, 300 mg, and 600 mg strengths for flexible dosing.
Extended-release oral tablets in 150 mg, 300 mg, and 600 mg strengths designed for once or twice daily dosing with consistent plasma levels.
Packaging includes dosing syringes for accurate liquid administration.
Oral tablets and suspensions supplied in blister packs or bottles, depending on formulation.
Extended-release tablets should be swallowed whole; not to be crushed, chewed, or broken.
Storage: store all formulations at room temperature, away from moisture and heat, and out of reach of children.
Disposal instructions emphasize discarding unused oral suspension after 7 weeks to ensure potency and safety.
Instructions include patient education materials on proper use, adherence, and side effect monitoring.
Some branded preparations include patient assistance programs and pricing support for access.
Multiple generic formulations exist with bioequivalence to branded products.
Labeling includes warnings about potential for serious skin reactions and necessary medical follow-up.
Professional monographs and prescribing information provide comprehensive details on pharmacokinetics and dosing guidance.
Preparations are designed to suit diverse clinical needs, including pediatric, adult, and extended-release options.
Patient information leaflets emphasize monitoring and adherence to dosing schedules, avoiding abrupt discontinuation.